Savara’s (SVRA) “Market Outperform” Rating Reiterated at JMP Securities

Savara (NASDAQ:SVRA)‘s stock had its “market outperform” rating restated by equities research analysts at JMP Securities in a note issued to investors on Thursday, Benzinga reports. They presently have a $8.00 target price on the stock. JMP Securities’ price target suggests a potential upside of 66.32% from the company’s current price.

Separately, Piper Sandler increased their price target on Savara from $7.00 to $16.00 and gave the company an “overweight” rating in a report on Monday, March 4th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Savara has an average rating of “Buy” and an average target price of $8.20.

Savara Stock Up 0.4 %

Shares of SVRA opened at $4.81 on Thursday. The company has a market capitalization of $664.50 million, a price-to-earnings ratio of -14.58 and a beta of 0.77. The stock’s 50-day moving average price is $4.97 and its 200-day moving average price is $4.40. The company has a quick ratio of 15.66, a current ratio of 15.66 and a debt-to-equity ratio of 0.19. Savara has a 52 week low of $1.76 and a 52 week high of $5.70.

Savara (NASDAQ:SVRA) last announced its earnings results on Thursday, March 7th. The company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.02. On average, sell-side analysts predict that Savara will post -0.38 EPS for the current year.

Institutional Trading of Savara

Hedge funds and other institutional investors have recently bought and sold shares of the business. Sivia Capital Partners LLC acquired a new position in Savara in the 4th quarter valued at about $169,000. Vanguard Group Inc. boosted its stake in shares of Savara by 2.6% during the 4th quarter. Vanguard Group Inc. now owns 5,914,947 shares of the company’s stock worth $27,800,000 after acquiring an additional 150,346 shares in the last quarter. Wellington Management Group LLP purchased a new stake in shares of Savara during the 4th quarter worth approximately $9,683,000. Goldman Sachs Group Inc. boosted its stake in shares of Savara by 44.0% during the 4th quarter. Goldman Sachs Group Inc. now owns 127,200 shares of the company’s stock worth $598,000 after acquiring an additional 38,895 shares in the last quarter. Finally, Barclays PLC boosted its stake in shares of Savara by 673.4% during the 4th quarter. Barclays PLC now owns 123,956 shares of the company’s stock worth $582,000 after acquiring an additional 107,928 shares in the last quarter. 87.93% of the stock is currently owned by institutional investors and hedge funds.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.